Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relenza Time-To-Alleviation Endpoint Not Perfect But Suitable - FDA's Jolson

Executive Summary

Glaxo's prospectively defined endpoint in Relenza studies may be imperfect but is appropriate, FDA Division of Anti-Viral Drug Products Director Heidi Jolson, MD, counseled the agency's Antiviral Drugs Advisory Committee Feb. 24.

You may also be interested in...



Relenza Cmte. Concerns Addressed In Labeling & Phase IV - FDA's Jolson

Issues raised by an FDA advisory committee regarding Glaxo's Relenza have been adequately addressed in labeling and through Phase IV commitments, FDA Division of Antiviral Drug Products Director Heidi Jolson, MD, said in a memo explaining FDA's July 27 approval of the influenza treatment despite the committee's recommendation against approval.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel